Welcome to our dedicated page for Interpace Biosciences news (Ticker: IDXG), a resource for investors and traders seeking the latest updates and insights on Interpace Biosciences stock.
Interpace Biosciences, Inc. (IDXG) is a molecular diagnostics company whose news flow centers on personalized medicine, thyroid cancer testing, and capital structure developments. Through its Interpace Diagnostics subsidiary, the company reports on clinical use of its molecular diagnostic tests, particularly its thyroid-focused platform built around ThyGeNEXT and ThyraMIRv2, as well as on financial performance and strategic responses to reimbursement changes.
News updates frequently include quarterly and annual financial results, where Interpace discusses net revenue, test volumes, cash collections, gross profit metrics, and non-GAAP measures such as Adjusted EBITDA. These releases often highlight trends such as record thyroid test volume, growth in thyroid-related revenue, and the impact of operational initiatives, including the use of AI and automation in laboratory processes as described by the company.
Investors and clinicians following IDXG news will also see regulatory and reimbursement announcements, such as company responses to Medicare Local Coverage Determinations affecting its PancraGEN test and the resulting restructuring toward a thyroid-only diagnostics business. Interpace’s communications explain how coverage decisions influence its test portfolio and outline its plans to remain sustainable and profitable based on its thyroid testing franchise.
Another key category of news involves scientific and clinical data presentations. Interpace reports on posters and studies presented at professional meetings, including large real-world analyses of ThyGeNEXT and ThyraMIRv2 in indeterminate thyroid nodules and institutional experiences using archival cytology slides. These items describe how the company’s combination platform refines malignancy risk and supports physician decision-making, according to the data presented.
Capital and balance sheet updates also feature in IDXG news, including announcements about early repayment of a term loan facility with BroadOak Capital Partners. Readers who monitor this page can review a chronological record of these financial, clinical, and strategic developments as disclosed by Interpace in its press releases.
Interpace Biosciences (OTCQX: IDXG) has partnered with Miroculus and Twist Bioscience to enhance next generation sequencing (NGS) library preparation through the use of digital microfluidics technology. This collaboration aims to automate and optimize genetic testing processes for Endocrine and GI cancers, reducing technician involvement and accelerating testing. Interpace's goal is to establish a high-throughput automated facility to improve productivity and decrease costs, leveraging advanced technologies from its partners.
Interpace Biosciences reported its 2021 financial results, revealing a 28% increase in net revenue to $41.3 million. The fourth quarter also showed 13% growth in net revenue at $10.9 million. The company improved its net loss to $(14.9 million), up from $(26.5 million) in 2020. Cash collections surged by 31% to $43.1 million, and gross profit margins improved significantly. Despite challenges with insurance reimbursements for their Thyroid tests, CMS has confirmed retroactive billing adjustments for 2022. Interpace aims for continued growth and efficiency in 2022.
Interpace Biosciences (OTCQX: IDXG) announced a policy update from the National Correct Coding Initiative (NCCI), allowing them to bill for the ThyGeNEXT and ThyraMIR tests under the Laboratory Coverage Determination (LCD) retroactively from January 1, 2022. This decision alleviates potential financial impacts on the company for 2022, as stated by CEO Tom Burnell, who emphasized the importance of preventing beneficiary access issues for Medicare-covered thyroid testing.
Interpace Biosciences (OTCQX: IDXG) has terminated its rights offering and standby purchase agreement with 3K Limited Partnership due to a new billing policy by the Centers for Medicare & Medicaid Services (CMS). This policy disallows reimbursements for the ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider on the same date. The company is assessing the policy's financial impact and preparing an appeal. CEO Tom Burnell expressed disappointment but emphasized efforts to secure alternative financing.
Interpace Biosciences (OTCQX: IDXG) announced the appointment of Vijay Aggarwal, Ph.D. to its Board of Directors, effective February 1, 2022. He replaces Eric B. Lev and brings over 30 years of experience in pharmaceutical services and clinical diagnostics. Dr. Aggarwal's previous roles include leadership positions at Vaxigenix and Aureon Laboratories. His expertise is expected to enhance Interpace's growth in clinical and pharmaceutical services. Thomas Burnell, CEO, expressed confidence in Dr. Aggarwal's contributions to the company's anticipated expansion in personalized medicine.
Interpace Biosciences has initiated a $30 million Rights Offering to enhance its liquidity, fund growth, and support general corporate needs. Eligible shareholders can purchase 0.75 shares of common stock at $6.65 per share, with rights expiring on February 2, 2022. A standby purchase agreement with 3K Limited Partnership ensures that unsubscribed shares will be purchased at $6.50. This move aims to secure funding for strategic investments and partnerships. Further details are outlined in the prospectus filed with the SEC.
Interpace Biosciences (OTCQX: IDXG) announced a proposed $30 million Rights Offering, effective January 10, 2022, to provide growth capital and enhance financial flexibility. Each eligible shareholder will receive non-transferable subscription rights to purchase 0.75 shares of common stock. The offering aims to fund product line acquisitions to support growth. The company anticipates securing a standby purchase agreement with 3K Limited Partnership, which owns approximately 18.7% of outstanding common shares. Details on pricing and subscription dates will be disclosed in a future release.
Interpace Biosciences reported Q3 2021 revenue of $9.5 million, a 15% increase year-over-year, with year-to-date revenue reaching $30.5 million, up 34%. The company achieved record cash collections for the second consecutive quarter and improved liquidity with a $7.5 million credit facility from Comerica Bank and a new $8 million term loan from BroadOak Fund. The firm plans a $30 million Rights Offering to maintain shareholder ownership. Despite a decline in pharma services, gross profit rose to 44% year-to-date, indicating strong operational performance.
Interpace Biosciences (OTCQX: IDXG) has secured an $8 million term loan from BroadOak Fund V, L.P. The loan aims to repay existing short-term promissory notes to private equity stockholders, enhancing the Company's liquidity without equity dilution. Coupled with a $7.5 million revolving credit facility from Comerica Bank, this financing strategy is aimed at improving operational flexibility. The BroadOak Loan has a three-year maturity and is secured by the Company's assets, emphasizing BroadOak's confidence in Interpace's growth trajectory.
Interpace Biosciences announced the granting of US Patent 11,143,657 for its PancraGEN technology, aimed at improving the diagnosis and management of pancreatic cysts. This patent enhances the molecular diagnostic capabilities of PancraGEN®, which has been used on over 40,000 cyst samples, boasting a 90% accuracy in risk assessment. The technology aims to better handle pancreatic cancer, a leading cause of cancer deaths in the U.S. This patent solidifies Interpace’s role in personalized medicine, targeting effective cancer diagnosis and treatment solutions.